Iron Mountain Incorporated is trading at a high multiple and its cash flow generation is poor. Click here to read why IRM ...

Emerging Growth Conference 88 December 11, 2025 9:05 AM ESTCompany ParticipantsJean-Marie Clouet - Vice President ...

Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...

Perimeter Solutions, Inc. (NYSE: PRM) ('Perimeter,” 'Perimeter Solutions,” or the 'Company”), today announced that it has entered into a definitive agreement to acquire Medical Manufacturing ...

Gov Hyacinth Iormem Alia of Benue State has said that he is determined to fix the broken Benue, some indigenes believed him ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

MPACT’s VivoCity reported positive rental reversion of 14.1% in 2QFY2026 ended Sept 30. UOBKH thinks MPACT will be acquired ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

With the right metrics, you can increase the return on both. by Jim Stengel, Cait Lamberton and Ken Favaro Over the past 20 years, performance marketing has become the dominant approach companies use ...